1. ”A good diagnosis is half the cure”
Interim report - First nine months of 2017
November 7, 2017

2. Forward looking statements
This presentation contains forward-looking statements. Words such as “believe”, “expect”, “may”, “plan”, “strategy”, “estimate”, “target” and “plan” and similar expressions identify such forward-looking statements. Statements other than historical facts included in this presentation concerning our plans, objectives, goals, future events and performance are forward looking statements. They involve risks, uncertainties and other factors, which may cause actual results, performance and achievements to differ materially from the results discussed in the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date of this presentation.

3. Highlights 1-9M 2017 (Q3)
Progress on FDA process
Future focus and 2017 milestones

4. Highlights for first nine months of 2017 (Q3)
Very strong revenue growth continues
Revenue of DKK 18.3m in first nine months of 2017, equal 27% growth (Q3: 30%)
Strong sales momentum in NGAL (9M: +84%) and antibodies (9M: +33%)
EBIT of DKK -28.3m, against DKK -20.3m last year
High activity related to FDA process and US organization
Continued strong news flow
New AKI article published in Canada
FDA process on track
More than 60% of patients enrolled by end-October 2017
New share issue strengthens liquidity in preparation for US commercial roll-out
Cash position of September 30, 2017 of DKK 13.3m
In October 2017, a direct share issue with net proceeds of DKK 41.0m was conducted

5. Strong sales momentum sustained in Q3 2017
BioPorto continued to expand sales in Q3 2017, mainly within The NGAL Test™ and antibodies
Revenue in Q of DKK 6.0m, corresponding to growth of 30% and in 9M 2017 of DKK 18.3m, corresponding to growth of 27%
Quarterly revenue (DKKm)
Revenue (DKKm, LTM)
2016
2017 23
6.6
6.3
5.7
6.0
5.2
4.7 21
4.6 18 Q1 Q2 Q3 Q4
Q1 2015Q1 2015
Q2 2015Q2 2015
Q3 2015Q3 2015
Q4 2015Q4 2015
Q1 2016Q1 2016
Q2 2016Q2 2016
Q3 2016Q3 2016
Q4 2016Q4 2016
Q1 2017Q1 2017
Q2 2017Q2 2017
Q3 2017Q3 2017

6. US sales increase of +388% YoY of The NGAL Test™ and bulk-orders of antibodies drives growth
Revenue by product (DKKm), first nine months 2017
+31%
2016
2017
9.4
7.2
+84%
-2%
4.2
4.2
4.1
2.3
-19%
0.8
0.6
The NGAL Test™
ELISA kits
Antibodies
Other products and licensesOther products and licenses

7. US is driving growth in sales of The NGAL Test™ backed by solid performance in ROW
Sales to Research Use Only (RUO) continues to be the most important growth-driver for The NGAL Test™ - has increase sales by +388% YTD YoY
Knowledge of solution is increasing among US clinics and physicians
Local presence support educational efforts and academic position
16 US hospitals and clinics as regular users by end-September 2017
YTD sales of The NGAL Test™ outside US has increased an healthy 33%

8. New strategy delivers growth in antibodies
Antibody sales was up 58% in Q and 31% in the first nine months of 2017 – result of impact strategy focused at assay developers and large quantity orders
Sales of ELISA kits on par YTD but down 27% in Q3 2017, as ELISA Human NGAL kits are experiencing a shift towards turbidimetry platforms

9. Strong support for NGAL and improved AKI treatment
: NGAL Demonstrates Positive Economic Outcomes: Greatly Reduces Costs Associated With Diagnosis and Treatment of Acute Kidney Injury.
: Strong data from previous NGAL study provides the basis for new protocol and FDA registration application.
: Impact of Near Real-Time NGAL assessment on Clinical Practice.
: Health care resource use associated with AKI is needed to frame the investment and cost-effectiveness of strategies to prevent AKI and promote kidney recovery (Clinical Journal of the American Society of Nephrology)

10. High activity related to FDA process and US organization increase operating loss
EBIT of DKK -28.3m, against DKK -20.3m last year
Capacity cost was DKK 41.6m YTD against DKK 30.9m last year due to US clinical studies and higher operational costs in US subsidiary
Cash position end-September 2017 at DKK 13.3m
Quarterly EBIT (DKKm)
2016
2017
-4.8
-5.4
-7.1
-7.7
-8.4
-9.2
-10.7 Q1 Q2 Q3 Q4

11. New share issue with net proceeds of DKK 41
New share issue with net proceeds of DKK 41.0m to prepare for commercial roll-out in US
In October 2017 a direct share issue of 13,015,625 new shares was conducted (9.13% of outstanding share capital prior to increase) at an offering price of 3.20 with gross proceeds of DKK 41.7m
Net proceeds will be allocated to
Support existing uptrend shown in current sales
Addition of extra resources in US and ROW
Launch activities in connection with expected FDA-approval
Bring BioPorto’s processes and procedures up to FDA requirement level
Build stronger instrument platform to support business growth
Strengthen BioPorto’s overall liquidity

12. Highlights 1-9M 2017 (Q3)
Progress on FDA process
Future focus and 2017 milestones

13. Majority of patients enrolled in US clinical study for The NGAL Test™
17 clinical sites participating in clinical trials
First patients recruited in April 2017
By mid-August 25% had been enrolled
By end-October +60% are recruited
Enrollment expected to be finalized by late-2017 or early-2018
Application expected to be submitted to FDA in Q1 2018

14. Process for FDA approval of The NGAL TestTM  
Nov.
2016
Jan.
2017
Q2 2017
Financing
Finalize design of protocol after feedback from FDA
Clinical trials to commence
Questions from FDA
Submission of application
Clinical studies finalized Q2
2018
Q1 2018
End-2017
Answers to FDA
Approval expected Q2
2018
Mid-2018

15. Highlights 1-9M 2017 (Q3)
Progress on FDA process
Future focus and 2017 milestones

16. On track for FY2017 guidance - focus on sustaining strategic momentum and sales in 2017
2018 and on
Primary targets
Completion of protocol for FDA study in Q1
Initiate enrolment of patients for clinical trials for The NGAL Test™ in Q2
Increase number of users of NGAL in Europe and Asia
Increase number or RUO of NGAL in US
Launch new NGAL and innate immune defense products
Submit FDA registration of The NGAL Test™ in Q2
Registration approval mid-2018
Increase number of distribution agreements for NGAL
Secondary targets
Increase sales of ELISA kits
Expand portfolio of antibodies
New license and OEM agreements
Continued expansion of antibody and ELISA portfolio
Growth
20-35%
Maintain high growth rates      

17. Sales and EBIT guidance maintained for 2017
Turnover expected in DKK 26-28m range
Growth of 25-35% primarily driven by higher sales of The NGAL Test™ (RUO in US, Siemens and own sales in Europe/Asia)
Healthy growth of antibodies and ELISA kits
EBIT loss of DKK 28-35m

18. Financial calendar: Annual report: March 8 2018
Q&A
Financial calendar:
Annual report: March